Selected research
Industry Research
Bio-based Hemostatic Powder Industry Research Report 2026
Market perspective
The global Bio-based Hemostatic Powder market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bio-based Hemostatic Powder is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bio-based Hemostatic Powder is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bio-based Hemostatic Powder is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bio-based Hemostatic Powder include BD, Lanhine Medical, Yancheng Yankang Medical Equipment, Success Bio-Tech, Johnson & Johnson, Haiyuan Hairun, Beijing Aitekang Medical Technology, Baxter and Medtronic, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bio-based Hemostatic Powder market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bio-based Hemostatic Powder Market by Company
BD
Lanhine Medical
Yancheng Yankang Medical Equipment
Success Bio-Tech
Johnson & Johnson
Haiyuan Hairun
Beijing Aitekang Medical Technology
Baxter
Medtronic
MedTrade Products
Hemostasis
BioCer Entwicklungs-GmbH
Bio-based Hemostatic Powder Segment by Type
Oxidized Cellulose
Polysaccharides
Other
Bio-based Hemostatic Powder Segment by Application
Surgery
First Aid
Bio-based Hemostatic Powder Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bio-based Hemostatic Powder market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bio-based Hemostatic Powder and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bio-based Hemostatic Powder.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bio-based Hemostatic Powder manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bio-based Hemostatic Powder by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bio-based Hemostatic Powder in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oxidized Cellulose
- Polysaccharides
- Other
Applications
- Surgery
- First Aid
Companies covered
- BD
- Lanhine Medical
- Yancheng Yankang Medical Equipment
- Success Bio-Tech
- Johnson & Johnson
- Haiyuan Hairun
- Beijing Aitekang Medical Technology
- Baxter
- Medtronic
- MedTrade Products
- Hemostasis
- BioCer Entwicklungs-GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bio-based Hemostatic Powder Market Size (2021-2032)
- 2.2.2 Global Bio-based Hemostatic Powder Sales (2021-2032)
- 2.2.3 Global Bio-based Hemostatic Powder Market Average Price (2021-2032)
- 2.3 Bio-based Hemostatic Powder by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oxidized Cellulose
- 2.3.3 Polysaccharides
- 2.3.4 Other
- 2.4 Bio-based Hemostatic Powder by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Surgery
- 2.4.3 First Aid
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bio-based Hemostatic Powder Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bio-based Hemostatic Powder Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Bio-based Hemostatic Powder Revenue of Manufacturers (2021-2026)
- 3.4 Global Bio-based Hemostatic Powder Average Price by Manufacturers (2021-2026)
- 3.5 Global Bio-based Hemostatic Powder Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bio-based Hemostatic Powder, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bio-based Hemostatic Powder, Product Type & Application
- 3.8 Global Manufacturers of Bio-based Hemostatic Powder, Established Date
- 3.9 Global Bio-based Hemostatic Powder Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BD
- 4.1.1 BD Company Information
- 4.1.2 BD Business Overview
- 4.1.3 BD Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BD Bio-based Hemostatic Powder Product Portfolio
- 4.1.5 BD Recent Developments
- 4.2 Lanhine Medical
- 4.2.1 Lanhine Medical Company Information
- 4.2.2 Lanhine Medical Business Overview
- 4.2.3 Lanhine Medical Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Lanhine Medical Bio-based Hemostatic Powder Product Portfolio
- 4.2.5 Lanhine Medical Recent Developments
- 4.3 Yancheng Yankang Medical Equipment
- 4.3.1 Yancheng Yankang Medical Equipment Company Information
- 4.3.2 Yancheng Yankang Medical Equipment Business Overview
- 4.3.3 Yancheng Yankang Medical Equipment Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Yancheng Yankang Medical Equipment Bio-based Hemostatic Powder Product Portfolio
- 4.3.5 Yancheng Yankang Medical Equipment Recent Developments
- 4.4 Success Bio-Tech
- 4.4.1 Success Bio-Tech Company Information
- 4.4.2 Success Bio-Tech Business Overview
- 4.4.3 Success Bio-Tech Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Success Bio-Tech Bio-based Hemostatic Powder Product Portfolio
- 4.4.5 Success Bio-Tech Recent Developments
- 4.5 Johnson & Johnson
- 4.5.1 Johnson & Johnson Company Information
- 4.5.2 Johnson & Johnson Business Overview
- 4.5.3 Johnson & Johnson Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Johnson & Johnson Bio-based Hemostatic Powder Product Portfolio
- 4.5.5 Johnson & Johnson Recent Developments
- 4.6 Haiyuan Hairun
- 4.6.1 Haiyuan Hairun Company Information
- 4.6.2 Haiyuan Hairun Business Overview
- 4.6.3 Haiyuan Hairun Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Haiyuan Hairun Bio-based Hemostatic Powder Product Portfolio
- 4.6.5 Haiyuan Hairun Recent Developments
- 4.7 Beijing Aitekang Medical Technology
- 4.7.1 Beijing Aitekang Medical Technology Company Information
- 4.7.2 Beijing Aitekang Medical Technology Business Overview
- 4.7.3 Beijing Aitekang Medical Technology Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Beijing Aitekang Medical Technology Bio-based Hemostatic Powder Product Portfolio
- 4.7.5 Beijing Aitekang Medical Technology Recent Developments
- 4.8 Baxter
- 4.8.1 Baxter Company Information
- 4.8.2 Baxter Business Overview
- 4.8.3 Baxter Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Baxter Bio-based Hemostatic Powder Product Portfolio
- 4.8.5 Baxter Recent Developments
- 4.9 Medtronic
- 4.9.1 Medtronic Company Information
- 4.9.2 Medtronic Business Overview
- 4.9.3 Medtronic Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Medtronic Bio-based Hemostatic Powder Product Portfolio
- 4.9.5 Medtronic Recent Developments
- 4.10 MedTrade Products
- 4.10.1 MedTrade Products Company Information
- 4.10.2 MedTrade Products Business Overview
- 4.10.3 MedTrade Products Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 MedTrade Products Bio-based Hemostatic Powder Product Portfolio
- 4.10.5 MedTrade Products Recent Developments
- 4.11 Hemostasis
- 4.11.1 Hemostasis Company Information
- 4.11.2 Hemostasis Business Overview
- 4.11.3 Hemostasis Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hemostasis Bio-based Hemostatic Powder Product Portfolio
- 4.11.5 Hemostasis Recent Developments
- 4.12 BioCer Entwicklungs-GmbH
- 4.12.1 BioCer Entwicklungs-GmbH Company Information
- 4.12.2 BioCer Entwicklungs-GmbH Business Overview
- 4.12.3 BioCer Entwicklungs-GmbH Bio-based Hemostatic Powder Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BioCer Entwicklungs-GmbH Bio-based Hemostatic Powder Product Portfolio
- 4.12.5 BioCer Entwicklungs-GmbH Recent Developments
5 Global Bio-based Hemostatic Powder Market Scenario by Region
- 5.1 Global Bio-based Hemostatic Powder Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bio-based Hemostatic Powder Sales by Region: 2021-2032
- 5.2.1 Global Bio-based Hemostatic Powder Sales by Region: 2021-2026
- 5.2.2 Global Bio-based Hemostatic Powder Sales by Region: 2027-2032
- 5.3 Global Bio-based Hemostatic Powder Revenue by Region: 2021-2032
- 5.3.1 Global Bio-based Hemostatic Powder Revenue by Region: 2021-2026
- 5.3.2 Global Bio-based Hemostatic Powder Revenue by Region: 2027-2032
- 5.4 North America Bio-based Hemostatic Powder Market Facts & Figures by Country
- 5.4.1 North America Bio-based Hemostatic Powder Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bio-based Hemostatic Powder Sales by Country (2021-2032)
- 5.4.3 North America Bio-based Hemostatic Powder Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Bio-based Hemostatic Powder Market Facts & Figures by Country
- 5.5.1 Europe Bio-based Hemostatic Powder Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bio-based Hemostatic Powder Sales by Country (2021-2032)
- 5.5.3 Europe Bio-based Hemostatic Powder Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Bio-based Hemostatic Powder Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bio-based Hemostatic Powder Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bio-based Hemostatic Powder Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bio-based Hemostatic Powder Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bio-based Hemostatic Powder Market Facts & Figures by Country
- 5.7.1 South America Bio-based Hemostatic Powder Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bio-based Hemostatic Powder Sales by Country (2021-2032)
- 5.7.3 South America Bio-based Hemostatic Powder Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Bio-based Hemostatic Powder Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bio-based Hemostatic Powder Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bio-based Hemostatic Powder Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bio-based Hemostatic Powder Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Bio-based Hemostatic Powder Sales by Type (2021-2032)
- 6.1.1 Global Bio-based Hemostatic Powder Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Bio-based Hemostatic Powder Sales Market Share by Type (2021-2032)
- 6.2 Global Bio-based Hemostatic Powder Revenue by Type (2021-2032)
- 6.2.1 Global Bio-based Hemostatic Powder Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bio-based Hemostatic Powder Revenue Market Share by Type (2021-2032)
- 6.3 Global Bio-based Hemostatic Powder Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bio-based Hemostatic Powder Sales by Application (2021-2032)
- 7.1.1 Global Bio-based Hemostatic Powder Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Bio-based Hemostatic Powder Sales Market Share by Application (2021-2032)
- 7.2 Global Bio-based Hemostatic Powder Revenue by Application (2021-2032)
- 7.2.1 Global Bio-based Hemostatic Powder Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bio-based Hemostatic Powder Revenue Market Share by Application (2021-2032)
- 7.3 Global Bio-based Hemostatic Powder Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bio-based Hemostatic Powder Value Chain Analysis
- 8.1.1 Bio-based Hemostatic Powder Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bio-based Hemostatic Powder Production Mode & Process
- 8.2 Bio-based Hemostatic Powder Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bio-based Hemostatic Powder Distributors
- 8.2.3 Bio-based Hemostatic Powder Customers
9 Global Bio-based Hemostatic Powder Analyzing Market Dynamics
- 9.1 Bio-based Hemostatic Powder Industry Trends
- 9.2 Bio-based Hemostatic Powder Industry Drivers
- 9.3 Bio-based Hemostatic Powder Industry Opportunities and Challenges
- 9.4 Bio-based Hemostatic Powder Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst